Frederic M Quitkin
Affiliation: Columbia University
- Are there differences between women's and men's antidepressant responses?Frederic M Quitkin
Department of Therapeutics, New York State Psychiatric Institute and Columbia University College of Physicians and Surgeons, New York 10032, USA
Am J Psychiatry 159:1848-54. 2002..The study examined a large data set to determine whether patients' sex affected the outcome of antidepressant treatment...
- When should a trial of fluoxetine for major depression be declared failed?Frederic M Quitkin
Department of Therapeutics, New York State Psychiatric Institute, New York, NY 10032, USA
Am J Psychiatry 160:734-40. 2003..The authors sought to determine how many weeks a fluoxetine trial with no improvement should continue before treatment is changed...
- Predictors of relapse in a prospective study of fluoxetine treatment of major depressionPatrick J McGrath
Depression Evaluation Service, New York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032 1007, USA
Am J Psychiatry 163:1542-8. 2006..This study was designed to test the predictive value of response pattern prospectively and to examine the data for other predictors of relapse...
- Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatientsFrederic M Quitkin
Department of Therapeutics, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, USA
J Clin Psychiatry 66:670-6. 2005..This effectiveness study assessed remission rates in patients who had the opportunity to receive up to 3 antidepressant trials if unresponsive...
- Electroencephalographic alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: pre- and post-treatment findingsGerard E Bruder
Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, New York, USA
Biol Psychiatry 63:1171-7. 2008....
- Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatientsBonnie P Taylor
Depression Evaluation Service, New York State Psychiatric Institute, Department of Psychiatry, Columbia University College of Physicians and Surgeons, 1051 Riverside Dr, New York, NY 10032, USA
Am J Psychiatry 163:73-8. 2006..The authors hypothesized that since psychomotor slowing in depressed patients has been linked to reduced dopaminergic neurotransmission, patients with slowing would be unresponsive to fluoxetine, a selective serotonin reuptake inhibitor...
- Defining the boundaries of atypical depression: evidence from the HPA axis supports course of illness distinctionsJonathan W Stewart
New York State Psychiatric Institute, United States Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA
J Affect Disord 86:161-7. 2005....
- Dichotic listening tests of functional brain asymmetry predict response to fluoxetine in depressed women and menGerard E Bruder
Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
Neuropsychopharmacology 29:1752-61. 2004..Responder vs nonresponder differences for verbal dichotic listening in women and nonverbal dichotic listening in men are discussed in terms of differences in cognitive function, hemispheric organization, and neurotransmitter function...
- Do age of onset and course of illness define biologically distinct groups within atypical depression?Jonathan W Stewart
Department of Therapeutics, New York State Psychiatric Institute and Columbia University College of Physicians and Surgeons, USA
J Abnorm Psychol 112:253-62. 2003..Course of illness may usefully define more homogeneous depressive subgroups within atypical depression...
- Do age of onset and course of illness predict different treatment outcome among DSM IV depressive disorders with atypical features?Jonathan W Stewart
New York State Psychiatric Institute, New York, NY 10032, USA
Neuropsychopharmacology 26:237-45. 2002..Findings suggest that application of DSM IV atypical features might best be limited to those with early onset of chronic dysphoria...
- DSM-IV depression with atypical features: is it valid?Jonathan W Stewart
Department of Depression Evaluation Service, New York State Psychiatrist Institute, New York, NY 10032, USA
Neuropsychopharmacology 34:2625-32. 2009....
- Does dual antidepressant therapy as initial treatment hasten and increase remission from depression?Jonathan W Stewart
New York State Psychiatric Institute and Columbia University College of Physicians and Surgeons, New York, USA
J Psychiatr Pract 15:337-45. 2009..Only 30%-40% of depressed patients remit after 8 weeks of treatment with an antidepressant. We hypothesized that beginning treatment with two antidepressants would improve remission rates...
- "Outer-directed irritability": a distinct mood syndrome in explosive youth with a disruptive behavior disorder?Stephen J Donovan
Department of Therapeutics, New York State Psychiatric Institute, New York, NY 10032, USA
J Clin Psychiatry 64:698-701. 2003....
- Cognitive ERPs in depressive and anxiety disorders during tonal and phonetic oddball tasksGerard E Bruder
Department of Biopsychology, New York State Psychiatric Institute, Unit 50, 1051 Riverside Drive, New York, NY 10032, USA
Clin Electroencephalogr 33:119-24. 2002....
- Atypical depression: enhanced right hemispheric dominance for perceiving emotional chimeric facesGerard E Bruder
Department of Biopsychology, New York State Psychiatric Institute, New York 10032, USA
J Abnorm Psychol 111:446-54. 2002..This is further evidence that atypical depression is a biologically distinct subtype and underscores the importance of this diagnostic distinction for neurophysiologic studies...
- Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapseAndrew A Nierenberg
Havard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA
Neuropsychopharmacology 29:1012-8. 2004..The low relapse rate for patients with an acute placebo pattern switched to placebo suggests specific drug effect played a smaller role in their initial improvement...
- Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatmentDavid J Brunswick
The Depression Research Unit, University of Pennsylvania Medical Center, University Science Center, 8th Floor, 3600 Market Street, Philadelphia, PA 19104, USA
J Affect Disord 68:243-9. 2002..The purpose of this study was to investigate the relationship between steady-state plasma drug concentrations and outcome during relapse-prevention therapy with fluoxetine...
- Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implicationsCristina Cusin
Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
J Clin Psychiatry 68:52-7. 2007..While patterns of response have been examined as possible predictors of outcome, the clinical correlates and implications of early worsening per se have not been investigated...
- Selecting methodologies for the evaluation of differences in time to response between antidepressantsStuart A Montgomery
Imperial College School of Medicine, London, United Kingdom
J Clin Psychiatry 63:694-9. 2002..The delay in the therapeutic effect of antidepressants is a considerable impediment to their successful clinical use, and attention has recently been focused on antidepressant drugs that may have a faster onset of action...
- Accurate meta-analytical assessment of "true antidepressant effects" neededFrederic M Quitkin
J Clin Psychiatry 66:1192; author reply 1192-3. 2005
- A reappraisal of atypical depressionFrederic M Quitkin
Am J Psychiatry 160:798-800; author reply 800-1. 2003
- Substance use disorder comorbidity in major depressive disorder: an exploratory analysis of the Sequenced Treatment Alternatives to Relieve Depression cohortLori L Davis
VA Medical Center, Tuscaloosa, AL 35404, USA
Compr Psychiatry 46:81-9. 2005..In conclusion, gender, marital status, age of onset of major depression, functional impairment, and suicide risk factors differ in depressed patients with concurrent SUD symptoms compared to those without SUD comorbidity...
- Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) studyMaurizio Fava
Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
Psychiatr Clin North Am 26:457-94, x. 2003..This article provides the overall rationale for STAR*D and details the rationale for key design, measurement, and analytic features of the study...
- Sequenced treatment alternatives to relieve depression (STAR*D): rationale and designA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9086, USA
Control Clin Trials 25:119-42. 2004..Participants with an adequate symptomatic response may enter the 12-month naturalistic follow-up phase with brief monthly and more complete quarterly assessments...
- Electrolyte-balanced sports drink for polydipsia-hyponatremia in schizophreniaFrederic M Quitkin
Am J Psychiatry 160:385-6. 2003
- Do antihypertensives make tranylcypromine safer? Three case reportsBonnie P Taylor
J Clin Psychiatry 66:657-8. 2005